Extended indication for Xultophy
The summary of product characteristics (SPC) for Xultophy (liraglutide, insulin degludec; Novo Nordisk) now states that the product is indicated for use in patients who have failed to respond to glucose-lowering medicines combined with a GLP-1 receptor agonist. The updated SPC also contains dosing information for patients who are transferring from GLP-1 receptor agonists.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068999
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com